Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus

Journal of Virology

Volumn 76, Issue 22, 2002, Pages 11440-11446

  Fredericksen, Brenda L ^a   Wei, Bangdong L ^a   Yao, Jian ^a   Luo, Tianci ^a   Garcia, J Victor ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMMONIUM CHLORIDE; BAFILOMYCIN A1; CHLOROQUINE; CONCANAMYCIN A; CONCANAMYCIN B; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CONTROLLED STUDY; ENDOCYTOSIS; ENDOSOME; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNALIZATION; LONG TERMINAL REPEAT; LYSOSOME; MEMBRANE FUSION; MURINE LEUKEMIA VIRUS; NONHUMAN; PH; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS INFECTIVITY; VIRUS PARTICLE;

EID: 0036827862     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.22.11440-11446.2002     Document Type: Article

References (47)

1. Aoki, F. Y., and D. S. Sitar. 1988. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14:35-51.
2. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
3. Bloland, P. B., M. Ettling, and S. Meek. 2000. Combination therapy for malaria in Africa: Hype or hope? Bull. W. H. O. 78:1378-1388.
4. Daniels, R. S., J. C. Downie, A. J. Hay, M. Knossow, J. J. Skehel, M. L. Wang, and D. C. Wiley. 1985. Fusion mutants of the influenza virus hemagglutinin glycoprotein. Cell 40:431-439.
5. de Duve, C., T. de Barsy, B. Poole, A. Trouet, P. Tulkens, and F. Van Hoof. 1974. Lysosomotropic agents. Biochem. Pharmacol. 23:2495-2531.
6. Demicheli, V., T. Jefferson, D. Rivetti, and J. Deeks. 2000. Prevention and early treatment of influenza in healthy adults. Vaccine 18:957-1030.
7. Doms, R. W. 2000. Beyond receptor expression: The influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 276:229-237.
8. Drose, S., and K. Altendorf. 1997. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J. Exp. Biol. 200:1-8.
9. Drose, S., K. U. Bindseil, E. J. Bowman, A. Siebers, A. Zeeck, and K. Altendorf. 1993. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. Biochemistry 32:3902-3906.
10. Ducharme, J., and R. Farinotti. 1996. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet. 31:257-274.
11. Fackler, O. T., and B. M. Peterlin. 2000. Endocytic entry of HIV-1. Curr. Biol. 10:1005-1008.
12. Fleming, D. M. 2001. Managing influenza: Amantadine, rimantadine and beyond. Int. J. Clin. Pract. 55:189-195.
13. Frazier, A. L., and J. V. Garcia. 1994. Retrovirus-mediated transfer and long-term expression of HIV type 1 tat gene in murine hematopoietic tissues. AIDS Res. Hum. Retrovir. 10:1517-1519.
14. +-ATPase. Curr. Med. Chem. 6:1197-1212.
15. Garcia, J. V., and A. D. Miller. 1994. Retrovirus vector-mediated transfer of functional HIV-1 regulatory genes. AIDS Res. Hum. Retrovir. 10:47-52.
16. Grabe, M., and G. Oster. 2001. Regulation of organelle acidity. J. Gen. Physiol. 117:329-344.
17. Hernandez, L. D., L. R. Hoffman, T. G. Wolfsberg, and J. M. White. 1996. Virus-cell and cell-cell fusion. Annu. Rev. Cell Dev. Biol. 12:627-661.
18. Iwahashi, J., K. Tsuji, T. Ishibashi, J. Kajiwara, Y. Imamura, R. Mori, K. Hara, T. Kashiwagi, Y. Ohtsu, N. Hamada, H. Maeda, M. Toyoda, and T. Toyoda. 2001. Isolation of amantadine-resistant influenza A viruses (H3N2) from patients following administration of amantadine in Japan. J. Clin. Microbiol. 39:1652-1653.
19. Jordan, P., J. G. Brookes, G. Nikolic, and D. G. Le Couteur. 1999. Hydroxychloroquine overdose: Toxicokinetics and management. J. Toxicol. Clin. Toxicol. 37:861-864.
20. Kain, K. C., G. D. Shanks, and J. S. Keystone. 2001. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin. Infect. Dis. 33:226-234.
21. Kalyesubula, I., P. Musoke-Mudido, L. Marum, D. Bagenda, E. Aceng, C. Ndugwa, and K. Olness. 1997. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr. Infect. Dis. J. 16:876-881.
22. Kelly, J. C., G. S. Wasserman, W. D. Bernard, C. Schultz, and J. Knapp. 1990. Chloroquine poisoning in a child. Ann. Emerg. Med. 19:47-50.
23. Kielian, M., and S. Jungerwirth. 1990. Mechanisms of enveloped virus entry into cells. Mol. Biol. Med. 7:17-31.
24. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66:2232-2239.
25. Kooi, C., M. Cervin, and R. Anderson. 1991. Differentiation of acid-pH-dependent and -nondependent entry pathways for mouse hepatitis virus. Virology 180:108-119.
26. Kozak, S. L., E. J. Platt, N. Madani, F. E. Ferro, Jr., K. Peden, and D. Kabat. 1997. CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. J. Virol. 71:873-882.
27. Kramer, M. H., and H. O. Lobel. 2001. Antimalarial chemoprophylaxis in infants and children. Paediatr. Drugs 3:113-121.
28. Long, J. K., S. B. Mossad, and M. P. Goldman. 2000. Antiviral agents for treating influenza. Clevel. Clin. J. Med. 67:92-95.
29. Luginger, E., G. K. Wenning, S. Bosch, and W. Poewe. 2000. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Movement Disorders 15:873-878.
30. Luo, T., J. L. Douglas, R. L. Livingston, and J. V. Garcia. 1998. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: Implications for HIV-based gene transfer systems. Virology 241:224-233.
31. Makono, R., and S. Sibanda. 1999. Review of the prevalence of malaria in Zimbabwe with specific reference to parasite drug resistance (1984-96). Trans. R. Soc. Trop. Med. Hyg. 93:449-452.
32. Manes, S., G. del Real, R. A. Lacalle, P. Lucas, C. Gomez-Mouton, S. Sanchez-Palomino, R. Delgado, J. Alcami, E. Mira, and A. Martinez. 2000. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep. 1:190-196.
33. Maréchal, V., F. Clavel, J. M. Heard, and O. Schwartz. 1998. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J. Virol. 72:2208-2212.
34. Masuda, H., H. Suzuki, H. Oshitani, R. Saito, S. Kawasaki, M. Nishikawa, and H. Satoh. 2000. Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol. Immunol. 44:833-839.
35. Mellman, I., R. Fuchs, and A. Helenius. 1986. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 55:663-700.
36. Montalto, N. J., K. D. Gum, and J. V. Ashley. 2000. Updated treatment for influenza A and B. Am. Family Physician 62:2467-2476.
37. Munchau, A., and K. P. Bhatia. 2000. Pharmacological treatment of Parkinson's disease. Postgrad. Med. J. 76:602-610.
38. +-ATPase activities relative to virus infection. J. Leukoc. Biol. 64:302-310.
39. Okereke, C. S. 1999. Management of HIV-infected pregnant patients in malaria-endemic areas: Therapeutic and safety considerations in concomitant use of antiretroviral and antimalarial agents. Clin. Ther. 21:1456-1496.
40. Peden, K., M. Emerman, and L. Montagnier. 1991. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology 185:661-672.
41. Perez, L., and L. Carrasco. 1994. Involvement of the vacuolar H(+)-ATPase in animal virus entry. J. Gen. Virol. 75:2595-2606.
42. Platt, E. J., K. Wehrly, S. E. Kuhmann, B. Chesebro, and D. Kabat. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864.
43. Pless, D. D., and R. B. Wellner. 1996. In vitro fusion of endocytic vesicles: Effects of reagents that alter endosomal pH. J. Cell. Biochem. 62:27-39.
44. Schaeffer, E., R. Geleziunas, and W. C. Greene. 2001. Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J. Virol. 75:2993-3000.
45. Singer, I. I., S. Scott, D. W. Kawka, J. Chin, B. L. Daugherty, J. A. De Martino, J. DiSalvo, S. L. Gould, J. E. Lineberger, L. Malkowitz, M. D. Miller, L. Mitnaul, S. J. Siciliano, M. J. Staruch, H. R. Williams, H. J. Zweerink, and M. S. Springer. 2001. CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J. Virol. 75:3779-3790.
46. Skehel, J. J., and D. C. Wiley. 2000. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69:531-569.
47. Wetsteyn, J. C., P. J. De Vries, B. Oosterhuis, and C. J. Van Boxtel. 1995. The pharmacokinetics of three multiple dose regimens of chloroquine: Implications for malaria chemoprophylaxis. Br. J. Clin. Pharmacol. 39:696-699.